TABLE 2.
Hit Classification |
||||||||
---|---|---|---|---|---|---|---|---|
Chemical | CASRN | Total AUC | Median AC50 (μM) | # Hits | Strong (6–8) | Moderate (3–5) | Weak (1–2) | Inactive (0) |
Rosiglitazone | 122320-73-4 | 647.05 | 0.0610 | 8 | * | |||
Tributyltin Chloride | 1461-22-9 | 149.82 | 0.0100 | 7 | * | |||
Lactofen | 77501-63-4 | 140.61 | 29.21 | 8 | * | |||
Fentin | 76-87-9 | 125.23 | 0.0049 | 8 | * | |||
Diclofop-methyl | 51338-27-3 | 123.72 | 56.47 | 8 | * | |||
MEHP | 4376-20-9 | 120.78 | 52.46 | 8 | * | |||
Halosulfuron-methyl | 100784-20-1 | 98.01 | 40.65 | 6 | * | |||
Fludioxonil | 131341-86-1 | 97.36 | 18.77 | 8 | * | |||
Cyfluthrin | 68359-37-5 | 71.80 | 37.38 | 4 | * | |||
Flufenacet | 142459-58-3 | 56.49 | 51.87 | 5 | * | |||
Isoxaflutole | 141112-29-0 | 51.21 | 42.09 | 4 | * | |||
Triflumizole | 68694-11-1 | 45.82 | 8.46 | 6 | * | |||
Quinoxyfen | 124495-18-7 | 39.88 | 21.76 | 5 | * | |||
Piperonyl butoxide | 51-03-6 | 31.82 | 63.81 | 3 | * | |||
Pyraclostrobin | 175013-18-0 | 31.80 | 8.41 | 4 | * | |||
Tebufenozide | 112410-23-8 | 24.33 | 23.27 | 4 | * | |||
Isazofos | 42509-80-8 | 14.50 | 35.87 | 2 | * | |||
Triallate | 2303-17-5 | 13.25 | 67.51 | 2 | * | |||
S-Bioallethrin | 28434-00-6 | 10.38 | 26.18 | 2 | * | |||
Fenpyroximate | 111812-58-9 | 10.31 | 11.00 | 1 | * | |||
Boscalid | 188425-85-6 | 9.74 | 17.14 | 2 | * | |||
Pyridaben | 96489-71-3 | 8.75 | 6.10 | 1 | * | |||
Esfenvalerate | 66230-04-4 | 8.47 | 39.74 | 1 | * | |||
Dithiopyr | 97886-45-8 | 8.33 | 45.44 | 1 | * | |||
Bisphenol A | 80-05-7 | 6.99 | 77.66 | 1 | * | |||
Tebufenpyrad | 119168-77-3 | 6.74 | 16.10 | 1 | * | |||
Prochloraz | 67747-09-5 | 6.08 | 24.49 | 1 | * | |||
Indoxacarb | 173584-44-6 | 5.30 | 13.72 | 1 | * | |||
Asulam | 3337-71-1 | 0.00 | NA | 0 | * |
Summary values for chemical efficacy (AUC) and potency (AC50) are shown for the 26 chemical hits identified from the adipogenesis screen, as well as rosiglitazone and tributyltin positive controls (PC), and asulam negative control (NC). Hit frequency is reported across the 8 orthologous adipocyte endpoints, and are stratified into strong (6–8), moderate (3–5), weak (1–2), and inactive (0) hits.